CR20220376A - Moduladores de la monoacilglicerol lipasa - Google Patents
Moduladores de la monoacilglicerol lipasaInfo
- Publication number
- CR20220376A CR20220376A CR20220376A CR20220376A CR20220376A CR 20220376 A CR20220376 A CR 20220376A CR 20220376 A CR20220376 A CR 20220376A CR 20220376 A CR20220376 A CR 20220376A CR 20220376 A CR20220376 A CR 20220376A
- Authority
- CR
- Costa Rica
- Prior art keywords
- sup
- methods
- disorders
- monoacylglycerol lipase
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos de azabiciclo 3.1.0 y 4.1.0 de la Fórmula (I), composiciones farmacéuticas que los contienen, métodos para elaborarlos, y métodos para usarlos que incluyen métodos para tratar estados de enfermedad, trastornos, y afecciones asociados con la modulación de la MGL, tales como aquellos asociados con el dolor, los trastornos psiquiátricos, los trastornos neurológicos (incluidos, pero que no se limitan a, el trastorno depresivo mayor, la depresión resistente al tratamiento, la depresión ansiosa, el trastorno bipolar), los cánceres y las afecciones oculares en donde X, Y, R1, R2a y R2b se definen en la presente descripción. <img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAJ4AAAB5CAYAAADIxJhBAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAAA0XSURBVHhe7Z1ZaBRdFsevw7y4vLg9zIc6GgY3xLgGQYOC4vIyEQXBFyMuzIsKIi6ouICK6KCgIm4I8UEfRNEXN1QUI7iNURE1IiIqjqJREdEXmZ7+3dSJ9ZXVptNd1dW3cn7QVKqSrq7u/uecc88591aHTBajKCXmL95WUUqKCk9JBBWekggqPCURVHhKIqjwlERQ4SmJoMJTEkGFpySCCs9BXr9+bT5+/OjtuYkKzyGuX79uqqqqTO/evU337t3N9OnTzZEjR7zfuoUKzxHu3btnxo0bZyZMmGDq6+vNq1evzJw5c0xtba2T4tMmAUfAuvXv399s27bNO9LMyZMnzcyZM823b99Mx44dvaPlj1o8B/j+/bs5ffq0mTRpknfkJ7heaGxstFtXUOE5QFNTk9327dvXbv306tXLbp8/f263rqDCcwAR1/v37+3WD9YQKioq7NYVVHiOsHz5cutug1y7ds1uBwwYYLeuoIMLRyB3N2PGDPPHH39YEXbu3NmcOXPGrFmzxtTV1dkRrkuoxXME3C0jWEa2pFWGDx9ubt265aToQC2egxDX8ejWrZt3xD3U4jnG06dPbb4O0VE2k8GFa7Qr4REnuY5/EHHlyhVz9uxZb88t2oXwsAp79uwxu3bt8o6kg69fv5ouXbp4e27RLoS3c+dOc/HiRW8vPTx8+DA0qewCzguPkV7wQUHdD6O+YI1TSRbnhUeBnO6MGzdu2Ac/k2pYuHCh9xc/M/9K+ZAKVysWjcepU6fM+fPnzaFDh1IxmEgrqY7xOnXq5P2klBupEB4ultgON7tixQozZcoUs3nz5j8lWHv06GFqamq8PSVpUiE8kqoivu3bt1tXu3r1au+3zSDCsWPHentK0qQqxiO+o4C+du1aje/KnNTFeBs3bvzTVilPUic86pibNm2yo1pcbxohhqV0RojhKs4L78SJE2bIkCHeXjOTJ0+2cZ6r5aQwCB0YOA0dOtSsW7fOXLp0yXTo0MEsXbrUTQHSFqWUL9++fcvs3r07M3r06Ez2n8zu+6mvr7e/y8a2maamJu9o+ZM6V0tDQLBk5iK8D0KF8ePH2/1z587ZDuTgFEZG6levXrVWn0nePMeJVilPgKmhsbExU1NT4+1Fz6RJkzJZV56pq6vLNDQ0/GKBogArxnvAivF+8uXVq1f2OTyXaytnUulq+X+KQxCck3M/ePDAur0FCxbYfb7sbExpv/hiQGQiHMRXKIiOc/DPAZyX6w27Pq67mNcqlFQKD0G0xVLkC18owvCDGPniiMP4som3+Jlj+Yqf2Mwfx0UBry0xHz9zbj4XP4iOf5wkrGMqhceXGNUX6Cef82JV+EIRKF8qXzbPCftHQBD8TsSar1ALAXFxPXL9iJLX3bx5s90vNamc7EPqIfsl2hlZUcL6JXQy59tmRZCfFZzJumYb9L9588aegwHDly9fzP79++01LlmypCStW1u2bLHTIVmZYN++fbbSw8AkkTVXrPyUVhELUQycA2uYFVqmoqKi5C5OXC4hAV99HOFIvqRKeBJES2wjcLzYABrBROWWCPol8C814nKTen0hVXk85iDQkbx161bvSDMcD1v+oS3cuXOnJadWLCw7QQUiCYYNG2a3Y8aMsdukSF0CGWiNunDhgrcXDcRGgwYN8vYKh7mw1JFFAO2VVAqPJlBao6JaJ5haaHZ0GsnM/cePH9vra++kUngUziHocguFJtPq6mpvrziyMZYZNWqUt5cM2TjYdmQnSSqFR3rgwIEDkbncKGMy2vMHDx7s7SUDNd+k111JpfCAGEpcLvmzQiEXF1VMRn6RZcZ0umWKhQfichcvXmy3An1tPFi+vzXu3r1r2+mj4NGjR6HrGLdHUi08cblBmJ9RU1NjXTGVBASYq5WImCwqsbCMBpPNlSxePi8VSAI5yO86MEioUlclo89zg/VSjhfbdQKcl487znqsSzgvPL7IKLpReD6VCYRGwZ7qB4KjvBQFCDzYHdKeidXVkkcjBxbnVMP169ebrl27Ft0QwPOZi0unL9DNS2zXr18/u18sNApMmzbN21NisXhYIWkLkgeWI+qGQywTViQO98U5J06cmKmurrbXjzXEZQfrwPnC+y/WKqeJWCweVojVKuvq6mwLTtZl2QCdRaPzGUnmA+1J9+/ft4stxtHWwzlHjBhhUym8B+q01GunTp3a0h7F3I585jdg+UnpRN2m5TSeACODuIjThlk3rCAPAQtC7IMlaIsl4XnEYoVan3zBSoUNLDjGQARry3vlPbEf9rfAZ4HFVH4SeSMoDY+5buomv5OXpKogK3ViIW/fvm2ygrJ3KATpoJB5s9wuk7wa+TnOFXcilnmrrX080uyZFZd9L1g2ltQgbUJTARUCGjApkzHfV2kmNuGFnZaBxoABA6zrzSUa3NKHDx/s7ZPevXtn1/mlrQnIu/Xs2dOKL27RISiWOWvrx8NAikQxbpmOFpoL+Ke6efNm4mWqsgLhRQluk9OGBfziIoVcrimMZ8+eZSorK0vWtcv78IcFhcL17tixw9tThMgHF7hDCFsGf+/evS1ulMB80aJF1p3xkDIWRXSsJr/HQkprEwH+jx8/nLtnFzVeKd0pP4llsg8jV0awuJm5c+dalyktSmGxGW4N90tcKLe/pBUJ/LEfAp01a5ZZtmyZ/V2ccJ24eRdv1+QE1u7FgJSieAncK6O6trjWIIxgr169mhk5cmTso1lglBpWflOiwbnpjeTPADcdJ4xEyd3pKqLx4Fx3yvz5820cGPfSXJ8/f7YjaCUenBMeucFVq1bZikKcIGxdNT4+nBMeUGxHGHEuR8Z0yLhyhVw7rpzSG4MYYEQvP7cHnBQeVi87cDEbNmzwjkQLKRxG0XGByKhkHD582I72/d07cXbylBNOCg8I+im6x2ElqJxIvjEO6ICmfCaVDNJIgAiZiFNVVZV6ATorPCBPGMf9WkUIhYA1k6S4/yGjcZAuFY5VVla27CN2bvdO7pABVJpxWnh8YQcPHvT2ooMkdjFLPBAGkKXiQWKc9jAmHElLGAlzbvInbV2CvCbvi1F1mnFaeIBLCnNLuY7nA2KhyySKlA0DFKl+UMEB+hU (***)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062972484P | 2020-02-10 | 2020-02-10 | |
| PCT/EP2021/053062 WO2021160602A1 (en) | 2020-02-10 | 2021-02-09 | Monoacylglycerol lipase modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220376A true CR20220376A (es) | 2022-09-16 |
Family
ID=74595268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220376A CR20220376A (es) | 2020-02-10 | 2021-02-09 | Moduladores de la monoacilglicerol lipasa |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11708359B2 (es) |
| EP (1) | EP4103557B1 (es) |
| JP (1) | JP7795466B2 (es) |
| KR (1) | KR20220140581A (es) |
| CN (1) | CN115066422B (es) |
| AR (1) | AR121296A1 (es) |
| AU (1) | AU2021220539A1 (es) |
| BR (1) | BR112022015116A2 (es) |
| CA (1) | CA3169988A1 (es) |
| CL (1) | CL2022002136A1 (es) |
| CO (1) | CO2022011275A2 (es) |
| CR (1) | CR20220376A (es) |
| DO (1) | DOP2022000162A (es) |
| EC (1) | ECSP22062460A (es) |
| IL (1) | IL295447A (es) |
| JO (1) | JOP20220180A1 (es) |
| MX (1) | MX2022009804A (es) |
| PE (1) | PE20221576A1 (es) |
| PH (1) | PH12022552019A1 (es) |
| TW (1) | TW202140465A (es) |
| UY (1) | UY39066A (es) |
| WO (1) | WO2021160602A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202140465A (zh) * | 2020-02-10 | 2021-11-01 | 比利時商健生藥品公司 | 單醯基甘油脂酶調節劑 |
| CN115362151B (zh) | 2020-03-26 | 2025-02-11 | 詹森药业有限公司 | 作为单酰基甘油脂肪酶调节剂的芳基哌啶 |
| MX2022011903A (es) | 2020-03-26 | 2023-01-11 | Janssen Pharmaceutica Nv | Azaspirociclos como moduladores de monoacilglicerol lipasa. |
| WO2021191391A1 (en) | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Aminocyclobutanes as monoacylglycerol lipase modulators |
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| CA3228446A1 (en) | 2021-08-09 | 2023-02-16 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators for use in autism spectrum disorders |
| CA3242372A1 (en) | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2493637A1 (en) | 2002-07-25 | 2004-02-12 | Manuela Villa | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| EP2090576A1 (en) | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
| KR20140068243A (ko) * | 2011-09-30 | 2014-06-05 | 얀센 파마슈티카 엔.브이. | 대사 질환 및 관련 장애의 치료를 위한 모노아실글리세롤 리파제 억제제 |
| WO2017170830A1 (ja) | 2016-03-31 | 2017-10-05 | 武田薬品工業株式会社 | 複素環化合物 |
| EA036637B1 (ru) | 2016-03-31 | 2020-12-02 | Такеда Фармасьютикал Компани Лимитед | Гетероциклические спиросоединения, ингибирующие моноацилглицерин-липазу |
| GB201613163D0 (en) | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
| MX2020007318A (es) * | 2017-09-29 | 2020-08-24 | Takeda Pharmaceuticals Co | Compuesto heterociclico. |
| CN112272670B (zh) | 2019-04-16 | 2023-12-12 | 上海翰森生物医药科技有限公司 | 含二并环类衍生物抑制剂、其制备方法和应用 |
| TW202140465A (zh) | 2020-02-10 | 2021-11-01 | 比利時商健生藥品公司 | 單醯基甘油脂酶調節劑 |
| CN115362151B (zh) | 2020-03-26 | 2025-02-11 | 詹森药业有限公司 | 作为单酰基甘油脂肪酶调节剂的芳基哌啶 |
| MX2022011903A (es) | 2020-03-26 | 2023-01-11 | Janssen Pharmaceutica Nv | Azaspirociclos como moduladores de monoacilglicerol lipasa. |
| WO2021191391A1 (en) | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Aminocyclobutanes as monoacylglycerol lipase modulators |
-
2021
- 2021-02-09 TW TW110104960A patent/TW202140465A/zh unknown
- 2021-02-09 CA CA3169988A patent/CA3169988A1/en active Pending
- 2021-02-09 KR KR1020227031216A patent/KR20220140581A/ko not_active Withdrawn
- 2021-02-09 PE PE2022001698A patent/PE20221576A1/es unknown
- 2021-02-09 JP JP2022548400A patent/JP7795466B2/ja active Active
- 2021-02-09 CR CR20220376A patent/CR20220376A/es unknown
- 2021-02-09 UY UY0001039066A patent/UY39066A/es unknown
- 2021-02-09 US US17/171,559 patent/US11708359B2/en active Active
- 2021-02-09 MX MX2022009804A patent/MX2022009804A/es unknown
- 2021-02-09 CN CN202180013762.3A patent/CN115066422B/zh active Active
- 2021-02-09 AU AU2021220539A patent/AU2021220539A1/en active Pending
- 2021-02-09 EP EP21705124.2A patent/EP4103557B1/en active Active
- 2021-02-09 IL IL295447A patent/IL295447A/en unknown
- 2021-02-09 PH PH1/2022/552019A patent/PH12022552019A1/en unknown
- 2021-02-09 BR BR112022015116A patent/BR112022015116A2/pt unknown
- 2021-02-09 WO PCT/EP2021/053062 patent/WO2021160602A1/en not_active Ceased
- 2021-02-09 AR ARP210100333A patent/AR121296A1/es not_active Application Discontinuation
-
2022
- 2022-08-08 CL CL2022002136A patent/CL2022002136A1/es unknown
- 2022-08-09 EC ECSENADI202262460A patent/ECSP22062460A/es unknown
- 2022-08-09 JO JOP/2022/0180A patent/JOP20220180A1/ar unknown
- 2022-08-10 CO CONC2022/0011275A patent/CO2022011275A2/es unknown
- 2022-08-10 DO DO2022000162A patent/DOP2022000162A/es unknown
-
2023
- 2023-06-02 US US18/328,242 patent/US20230382902A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022009804A (es) | 2022-09-02 |
| CA3169988A1 (en) | 2021-08-19 |
| CN115066422B (zh) | 2024-11-22 |
| PH12022552019A1 (en) | 2023-11-29 |
| US11708359B2 (en) | 2023-07-25 |
| ECSP22062460A (es) | 2022-11-30 |
| US20230382902A1 (en) | 2023-11-30 |
| JOP20220180A1 (ar) | 2023-01-30 |
| EP4103557C0 (en) | 2026-02-18 |
| JP2023512729A (ja) | 2023-03-28 |
| BR112022015116A2 (pt) | 2022-09-27 |
| AU2021220539A1 (en) | 2022-10-06 |
| CO2022011275A2 (es) | 2022-08-30 |
| DOP2022000162A (es) | 2022-10-31 |
| TW202140465A (zh) | 2021-11-01 |
| IL295447A (en) | 2022-10-01 |
| PE20221576A1 (es) | 2022-10-06 |
| JP7795466B2 (ja) | 2026-01-07 |
| EP4103557A1 (en) | 2022-12-21 |
| EP4103557B1 (en) | 2026-02-18 |
| CL2022002136A1 (es) | 2023-02-03 |
| KR20220140581A (ko) | 2022-10-18 |
| UY39066A (es) | 2021-08-31 |
| WO2021160602A1 (en) | 2021-08-19 |
| CN115066422A (zh) | 2022-09-16 |
| US20210253565A1 (en) | 2021-08-19 |
| AR121296A1 (es) | 2022-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220376A (es) | Moduladores de la monoacilglicerol lipasa | |
| CR20210153A (es) | Moduladores de monoacilglicerol lipasa | |
| MX2023003240A (es) | Moduladores de monoacilglicerol lipasa de ciclobutilamida. | |
| MX2022011903A (es) | Azaspirociclos como moduladores de monoacilglicerol lipasa. | |
| MX2021003661A (es) | Moduladores de la monoacilglicerol lipasa. | |
| MX2022011904A (es) | Aminociclobutanos como moduladores de monoacilglicerol lipasa. | |
| MX2022011902A (es) | Moduladores de la monoacilglicerol lipasa. | |
| MX2022011901A (es) | Arilo piperidinas como moduladores de monoacilglicerol lipasa. | |
| EA201100461A1 (ru) | Спиро-трициклические соединения как модуляторы бета-секретазы и способы их использования | |
| EA201591614A1 (ru) | Соединения 1,3-оксазин-2-амина, конденсированные с перфторированным циклопропилом, в качестве ингибиторов бета-секретазы и способы их применения | |
| MX366855B (es) | Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso. | |
| MX2012010657A (es) | Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico. | |
| MX2024013240A (es) | Tratamiento de trastornos neurologicos | |
| MX2024010344A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa | |
| MX2023003165A (es) | Moduladores de la caseína cinasa 1 delta. | |
| MX2023002350A (es) | Composiciones y metodos para mejorar enfermedades y trastornos neurologicos. | |
| MX2024001839A (es) | Moduladores de monoacilglicerol lipasa para uso en trastornos del espectro autista. | |
| MX2023003170A (es) | Moduladores de la caseina cinasa 1 delta. | |
| Hagerman et al. | Case series: deep brain stimulation in patients with FXTAS | |
| RU2002132883A (ru) | Новые полициклические инданилимидазолы, обладающие альфа2 адренергической активностью | |
| MX2026002937A (es) | Nuevas fenilalquilaminas y su uso en el tratamiento de trastornos psiquiatricos | |
| WO2024077043A3 (en) | Modifying early-stage parkinson's disease progression with deep brain stimulation | |
| EA201992628A1 (ru) | Ингибиторы bcl6, полученные из бензимидазолона |